AstraZeneca Sees 2030 Goal on Track as Cancer Drugs Drive Growth
The drugmaker’s revenue rose 5% when adjusted for currency changes, driven by growth in oncology sales.
Connecting Global Economies
The drugmaker’s revenue rose 5% when adjusted for currency changes, driven by growth in oncology sales.